BioSpace News Archive

Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF Key milestone and validation for Evive’s novel biologic development capability and technology platform Key component of the asset’s BLA submission to receive regulatory approval from the FDA Completes robust development program involving 10 succe

CytoAgents a clinical-stage biotechnology company focused on development of pharmaceutical products for the treatment of viral infectious diseases, including COVID-19 and the resulting cytokine storm, announced today that it has received an investment to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to tr

RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid ASPECTS has received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category.

uLab Systems, the creator of uLab, the treatment planning software and aligner system designed for orthodontists, has announced two significant additions to their senior leadership team. Amir Abolfathi has been appointed as Chief Executive Officer and Nicola Downes has been appointed as Chief Financial Officer in preparation for uLab’s full-scale aligner launch in September.

The race is on to find a vaccine for COVID-19, the illness caused by the novel coronavirus.

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the initiation of the PROLIFT Lateral Expandable System prospective study.

BioLife Solutions, Inc. (NASDAQ: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the closing of its public offering of 5,951,250 shares of common stock at the public offering price of $14.50 per share

After 21 years as Arthritis Research Canada/Arthrite-recherche Canada’s scientific director, world-renowned scientist and rheumatologist, Dr. John Esdaile is handing the leadership reins over to Dr. Diane Lacaille MD,CM, MHSc, FRCPC.

- Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing - Secrist, Gengos and Englert join Cyteir leadership team, enhancing company’s scientific, strategic business development, and drug development expertise

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it has resumed the Phase 1b stage of its Phase 1a/1b clinical trial of CB4211, its lead candidate for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. In March 2019, the company announced the temporary pause of the clinical study in respons